178 related articles for article (PubMed ID: 11285115)
1. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.
Petersen TR; Buus S; Brunak S; Nissen MH; Sherman LA; Claesson MH
Scand J Immunol; 2001 Apr; 53(4):357-64. PubMed ID: 11285115
[TBL] [Abstract][Full Text] [Related]
2. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
3. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
[TBL] [Abstract][Full Text] [Related]
4. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
5. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
[TBL] [Abstract][Full Text] [Related]
6. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
8. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
Corbet S; Nielsen HV; Vinner L; Lauemoller S; Therrien D; Tang S; Kronborg G; Mathiesen L; Chaplin P; Brunak S; Buus S; Fomsgaard A
J Gen Virol; 2003 Sep; 84(Pt 9):2409-2421. PubMed ID: 12917462
[TBL] [Abstract][Full Text] [Related]
9. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
10. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
[TBL] [Abstract][Full Text] [Related]
11. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.
Sarobe P; Pendleton CD; Akatsuka T; Lau D; Engelhard VH; Feinstone SM; Berzofsky JA
J Clin Invest; 1998 Sep; 102(6):1239-48. PubMed ID: 9739058
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
13. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
14. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
15. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.
Petersen TR; Bregenholta S; Pedersen LO; Nissen MH; Claesson MH
Cancer Lett; 1999 Apr; 137(2):183-91. PubMed ID: 10374840
[TBL] [Abstract][Full Text] [Related]
16. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen.
Li Y; Zhou W; Du J; Jiang C; Xie X; Xue T; He Y
Cancer Immunol Immunother; 2015 Feb; 64(2):259-69. PubMed ID: 25376540
[TBL] [Abstract][Full Text] [Related]
17. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
Lustgarten J; Theobald M; Labadie C; LaFace D; Peterson P; Disis ML; Cheever MA; Sherman LA
Hum Immunol; 1997 Feb; 52(2):109-18. PubMed ID: 9077559
[TBL] [Abstract][Full Text] [Related]
18. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
19. Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine.
Brander C; Pichler WJ; Corradin G
Clin Exp Immunol; 1995 Jul; 101(1):107-13. PubMed ID: 7621579
[TBL] [Abstract][Full Text] [Related]
20. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.
Hernandez J; Garcia-Pons F; Lone YC; Firat H; Schmidt JD; Langlade-Demoyen P; Zanetti M
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12275-80. PubMed ID: 12218171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]